SCHEMBL27186153

SCHEMBL27186153

COc1c(-c2cnc[nH]2)cc(C(=O)O)c2n[nH]cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ECE1 P42892 1/20 0.40
▸ EGFR P00533 1/20 0.38
▸ FGFR1 P11362 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ METAP2 P50579 1/20 0.37
▸ IDO1 P14902 5/20 0.35
▸ FTO Q9C0B1 1/20 0.34
▸ PRKAG1 P54619 4/20 0.33
▸ PRKAA1 Q13131 4/20 0.33
▸ PRKAB1 Q9Y478 4/20 0.33
▸ HSP90AA1 P07900 1/20 0.32
▸ HSP90AB1 P08238 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ HSD17B10 Q99714 2/20 0.31
▸ PRKAB2 O43741 2/20 0.31
▸ PRKAA2 P54646 2/20 0.31
▸ PRKAG3 Q9UGI9 2/20 0.31
▸ PRKAG2 Q9UGJ0 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30853390 0.89 EGFR (0.37) ECE1EGFRFGFR1KDRMETAP2
SCHEMBL27187216 0.89 EGFR (0.39) ECE1EGFRFGFR1KDRMETAP2
SCHEMBL27186991 0.75 HSD17B10 (0.50) HSD17B10KDM4E
SCHEMBL27186383 0.71 BRD4 (0.38) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL27186394 0.70 ALDH1A1 (0.36) PRKAG1PRKAA1PRKAB1HSP90AA1GAA
SCHEMBL27186283 0.67 PRKAB2 (0.35) PRKAG1PRKAA1PRKAB1HSD17B10PRKAB2
SCHEMBL29168454 0.65 PKM (0.31) KDM4E
SCHEMBL29168406 0.65 CDC25B (0.48) GAAHSD17B10KDM4ECLK1
SCHEMBL27186349 0.63 NR4A2 (0.40) HSD17B10KDM4E
SCHEMBL27186983 0.63 KDM4E (0.38) HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2024-04-04 — — US disclosed
CN-117651701-A Novel substituted bicyclic aza heterocycles as SOS1 inhibitors 唯久生物技术(苏州)有限公司 2024-03-05 — — CN disclosed
WO-2022187266-A1 NOVEL SUBSTITUTED BICYCLI AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2022-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS SOS1, SOS2, KSR1 ECE1 2029/4885EGFR 1060/4885FGFR1 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback